A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
|Articles|April 7, 2014
UBC Named Preferred Oncology Research Partner
United BioSource Corp. has been named the preferred oncology research partner by RainTree Oncology Services Corp
Advertisement
United BioSource Corp. (UBC) has been named the preferred oncology research partner by RainTree Oncology Services Corp., a community oncology alliance. The alliance seeks to standardize research processes within the the RainTree community oncology setting, UBC will have access to patient data and will partner to administer prospective and retrospective observation studies, which will provide information about the safety and efficacy of medicine in daily clinical use. UBC is a subsidiary of Express Scripts.
Read the full release
Advertisement
Related to this article
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain underutilized despite their importance to interpretation.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
3
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
4
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
5